Myovant Sciences (MYOV) was Initiated by Barclays to “Overweight” and the brokerage firm has set the Price Target at $18. Barclays advised their investors in a research report released on Nov 21, 2016.
Many Wall Street Analysts have commented on Myovant Sciences. Robert W. Baird Initiated Myovant Sciences on Nov 21, 2016 to “Outperform”, Price Target of the shares are set at $20.Myovant Sciences was Initiated by JMP Securities to “Mkt Outperform” on Nov 21, 2016. Myovant Sciences was Initiated by Citigroup to “Buy” on Nov 21, 2016.